Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 9/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643142 | 0.80 | MAOB (0.42) | IDO1AGXTMAOBNR4A2PARP10 | |
| SCHEMBL21837629 | 0.79 | GAA (0.71) | CA12CA1CA2CA9 | |
| SCHEMBL3092949 | 0.79 | IDO1 (0.50) | IDO1APPCA2TAAR1 | |
| SCHEMBL2094071 | 0.78 | TAAR1 (0.45) | IDO1AGXTMAOBLOXL2MAOA | |
| SCHEMBL15689699 | 0.77 | IDO1 (0.52) | IDO1AGXTMAOBAPPNR4A2 | |
| SCHEMBL8816 | 0.77 | IDO1 (0.52) | IDO1AGXTMAOBAPPNR4A2 | |
| SCHEMBL3251305 | 0.77 | IDO1 (0.52) | IDO1AGXTMAOBCA12CA1 | |
| SCHEMBL513966 | 0.77 | CYP3A4 (0.52) | IDO1APP | |
| SCHEMBL8480 | 0.77 | IDO1 (0.52) | IDO1MAOBAPPCA12CA1 | |
| SCHEMBL7534888 | 0.77 | IDO1 (0.52) | IDO1AGXTMAOBAPPNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| EP-2137139-B1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEM (FR) | 2014-09-10 | — | — | EP | claimed |
| US-8609882-B2 | Process for deacetalisation of α aminoacetals | CLARIANT SPECIALITY FINE CHEMICALS (FRANCE) (FR) | 2013-12-17 | — | — | US | claimed |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2137139-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | Clariant Specialty Fine Chemicals (France) (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2009032840-A1 | FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | claimed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| WO-2008125486-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-10-23 | — | — | WO | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| EP-0636142-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | claimed |
| EP-0636144-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | claimed |
| WO-1993021209-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| WO-1993021210-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| WO-1993021214-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| WO-1993021213-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | claimed |
| US-5254558-A | Substituted 1,3-diazines as leukocyte elastase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | claimed |
| EP-0528633-A1 | Pyrimidinyl acetamides as elastase inhibitors | ZENECA LIMITED (GB) | 1993-02-24 | — | — | EP | claimed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | ALDH7A1, AADAT, AASDHPPT | IDO1 126/4885AGXT 114/4885MAOB 93/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | IDO1 2371/4885AGXT 197/4885MAOB 67/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | IDO1 3058/4885AGXT 3424/4885MAOB 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.